Google SSO gives you the quickest path into the IIPLA newsroom, your reading access, and member-level continuity across articles. The full login page is still available if you prefer another option.
USTR places Vietnam in highest concern category for IP violations, raising possibility of new trade investigation
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
Vietnam's Ministry of Foreign Affairs has called on the United States to offer an objective and balanced evaluation of the country's intellectual property protection efforts. The statement follows the U.S. government's decision to list Vietnam as a 'Priority Foreign Country' in its annual global IP report. Vietnamese…
India, May 02 : India has once again been placed on the United States Trade Representative’s (USTR) “Priority Watch List” in its latest annual review of intellectual property rights (IPR) protection and enforcement. The designation places India among six countries identified by the US as having significant concerns re…
The United States Trade Representative (USTR) has placed Vietnam on its 'priority foreign country' list for intellectual property concerns, marking the first such designation in over a decade. The move, detailed in the USTR's annual report, signals potential for a new trade investigation and highlights ongoing US conc…
The 2026 Special 301 Report highlights Thailand’s proactive enforcement and legislative reforms, though online piracy and patent backlogs remain concerns The 2026 Special 301 Report highlights Thailand’s proactive enforcement and legislative reforms, though online piracy and patent backlogs remain concerns.
The New York State Bar Association has opened registration for its 2025 Fall Intellectual Property Meeting, featuring panels on evolving brand licensing practices, advertising law challenges, and ethical considerations in AI use for legal services. The event, co-sponsored by Akerman LLP, will provide 3.0 MCLE credits…
Zydus Lifesciences Limited has finalized a comprehensive settlement with Astellas Pharma Inc., ending all US patent disputes over the bladder drug Myrbetriq (Mirabegron). The agreement requires Zydus to pay $120 million plus ongoing licensing fees until September 2027, allowing the company to continue marketing its ge…